GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » EPS (Diluted)

Tyra Biosciences (Tyra Biosciences) EPS (Diluted) : $-1.68 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences EPS (Diluted)?

Tyra Biosciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.35. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.68.

Tyra Biosciences's EPS (Basic) for the three months ended in Mar. 2024 was $-0.35. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.68.

Tyra Biosciences's EPS without NRI for the three months ended in Mar. 2024 was $-0.35. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.68.

During the past 3 years, the average EPS without NRIGrowth Rate was -57.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Tyra Biosciences's highest 3-Year average EPS without NRI Growth Rate was -57.50% per year. The lowest was -62.60% per year. And the median was -60.05% per year.


Tyra Biosciences EPS (Diluted) Historical Data

The historical data trend for Tyra Biosciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences EPS (Diluted) Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-0.40 -0.42 -1.91 -1.32 -1.62

Tyra Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.31 -0.49 -0.53 -0.35

Competitive Comparison of Tyra Biosciences's EPS (Diluted)

For the Biotechnology subindustry, Tyra Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyra Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's PE Ratio falls into.



Tyra Biosciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Tyra Biosciences's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-69.134-0)/42.705
=-1.62

Tyra Biosciences's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-18.192-0)/52.229
=-0.35

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tyra Biosciences  (NAS:TYRA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Tyra Biosciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyra Biosciences (Tyra Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its lead product candidate is TYRA-300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Executives
Daniel Bensen officer: Chief Operating Officer C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Todd Harris director, officer: Chief Executive Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alan Fuhrman officer: Chief Financial Officer C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Ali D. Fawaz officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J More director, 10 percent owner 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Alta Partners Nextgen Fund Ii, L.p. 10 percent owner 4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert L. Hudkins officer: Chief Technology Officer C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Melissa Mccracken director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008